{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:03:20Z","timestamp":1789185800815,"version":"build-2803163510"},"reference-count":93,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirality"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>S<\/jats:italic>\u2010(+)\u2010Methyl 2\u2010(2\u2010chlorophenyl)\u20102\u2010(6,7\u2010dihydrothieno[3,2\u2010<jats:italic>c<\/jats:italic>]pyridin\u20105(4<jats:italic>H<\/jats:italic>)\u2010yl)acetate, also known as (<jats:italic>S<\/jats:italic>)\u2010clopidogrel, is marketed under the trade names Plavix and Iscover. It is a potent thienopyridine\u2010class of antithrombotic and antiplatelet drug (antiaggregant). Among the two available stereoisomers of clopidogrel, for pharmaceutical activities only the <jats:italic>S<\/jats:italic>\u2010enantiomer is applicable, as no antithrombotic activity is observed in the <jats:italic>R<\/jats:italic>\u2010enantiomer and causes political upheavals and social turmoil in animal experiments. Worldwide sales of Plavix amounted to $6.4 billion yearly, which ranks second. Attributed to the increased demand of (<jats:italic>S<\/jats:italic>)\u2010clopidogrel drug, it provoked the synthetic community to devise facile synthetic approaches. This review aims to summarize the synthetic methods of (<jats:italic>S<\/jats:italic>)\u2010clopidogrel drug reported in the literature. The present review discusses the pros and cons of each synthetic methodology, which would be beneficial to the scientific community for further developments in the synthetic methodologies for (<jats:italic>S<\/jats:italic>)\u2010clopidogrel. In addition, the compilation approach of literature\u2010reported synthetic strategies of (<jats:italic>S<\/jats:italic>)\u2010clopidogrel in one platform is advantageous, supportive, and crucial for the synthetic community to elect the best synthetic methodology of (<jats:italic>S<\/jats:italic>)\u2010clopidogrel and to create new synthesis ideas.<\/jats:p>","DOI":"10.1002\/chir.22742","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T07:48:39Z","timestamp":1504684119000},"page":"684-707","source":"Crossref","is-referenced-by-count":37,"title":["Developments in the synthesis of the antiplatelet and antithrombotic drug (<i>S<\/i>)\u2010clopidogrel"],"prefix":"10.1002","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7112-9296","authenticated-orcid":false,"given":"Aamer","family":"Saeed","sequence":"first","affiliation":[{"name":"Department of Chemistry Quaid\u2010i\u2010Azam University\u201045320  Islamabad Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Shahzad","sequence":"additional","affiliation":[{"name":"Department of Chemistry Quaid\u2010i\u2010Azam University\u201045320  Islamabad Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Faisal","sequence":"additional","affiliation":[{"name":"Department of Chemistry Quaid\u2010i\u2010Azam University\u201045320  Islamabad Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-5229","authenticated-orcid":false,"given":"Fayaz Ali","family":"Larik","sequence":"additional","affiliation":[{"name":"Department of Chemistry Quaid\u2010i\u2010Azam University\u201045320  Islamabad Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham R.","family":"El\u2010Seedi","sequence":"additional","affiliation":[{"name":"Division of Pharmacognosy, Department of Medicinal Chemistry Uppsala University, Biomedical Centre  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervaiz Ali","family":"Channar","sequence":"additional","affiliation":[{"name":"Department of Chemistry Quaid\u2010i\u2010Azam University\u201045320  Islamabad Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2000.36.4.570198"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060020-00012"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200707030-00002"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-008-0006-1"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02171863"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068193"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/cen-v084n049.p017"},{"key":"e_1_2_4_9_1","unstructured":"Chemistry World.Business Roundup September 9th2008."},{"key":"e_1_2_4_10_1","unstructured":"CorrickS BurgR GlasbergG et al.Top 500 prescription medicines UBM Canon Newtown2011;6."},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/15533174.2015.1137028"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1993.018.02.197445"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135372"},{"key":"e_1_2_4_14_1","first-page":"107","article-title":"High\u2010speed electrochemically modulated liquid chromatography","volume":"505","author":"Achilleas M","year":"2004","journal-title":"Anal Chim Acta"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules15118144"},{"key":"e_1_2_4_16_1","unstructured":"Aubert D.;Ferrand C.;Maffrand J.Thieno (3 2\u2010c) pyridine derivatives process for their preparation and their therapeutical use. EP 99802.1983."},{"key":"e_1_2_4_17_1","unstructured":"BadorcA FrehelD inventors; Sanofi assignee.Dextro\u2010rotatory enantiomer of methyl alpha\u20105 (4 5 6 7\u2010tetrahydro (3 2\u2010c) thieno pyridyl)(2\u2010chlorophenyl)\u2010acetate and the pharmaceutical compositions containing it. United States patent US 4 847 265.1989."},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754050-00006"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650689"},{"key":"e_1_2_4_20_1","unstructured":"ValerianoM DaverioP BianchiS.U.S. Patent 2004\/0024012A1.2004."},{"key":"e_1_2_4_21_1","unstructured":"PandeyB LohrayVB LorhrayBB.U.S. Patent 2002\/0177712A1.2002."},{"key":"e_1_2_4_22_1","unstructured":"KumarA VyasKD BarveSG.WO Patent 2005\/104663A2.2005."},{"key":"e_1_2_4_23_1","unstructured":"CastaldiG BarrecaG BolognaA.U.S. Patent 2005\/0143414A1.2005."},{"key":"e_1_2_4_24_1","unstructured":"ValerianoM DaverioP BianchiS. U.S. Patent 6737411B2.2004."},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2006.03.079"},{"key":"e_1_2_4_26_1","unstructured":"DescampsM RadissonJ inventors; Sanofi assignee.Process for the preparation of an n\u2010phenylacetic derivative of tetrahydrothieno (3 2\u2010c) pyridine and its chemical intermediate. United States patent US 5 204 469.1993."},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471686743"},{"key":"e_1_2_4_28_1","unstructured":"OniciuDC DasseuxJL BarbarasR et al. inventors; Cerenis Therapeutics Holding Sa assignee.Compounds compositions and methods useful for cholesterol mobilisation. United States patent US 8 349 833.2013."},{"key":"e_1_2_4_29_1","unstructured":"BadorcA FrehelD inventors; Sanofi assignee.Dextro\u2010rotatory enantiomer of methyl alpha\u20105 (4 5 6 7\u2010tetrahydro (3 2\u2010c) thieno pyridyl)(2\u2010chlorophenyl)\u2010acetate and the pharmaceutical compositions containing it. United States patent US 4 847 265.1989."},{"key":"e_1_2_4_30_1","unstructured":"MukarramMS MerwadeYA KhanRA inventors; The Company Of Wockhard Limited assignee.Process for the manufacture of (+)\u2010(s)\u2010clopidogrel bisulfate form\u20101. United States patent US 7 291 735.2007."},{"key":"e_1_2_4_31_1","unstructured":"ValerianoM DaverioP BianchiS inventors; TEVA Gy\u00f3gyszergy\u00e1r Z\u00e1rtk\u00f6r\u0171en M\u0171k\u00f6d\u0151 R\u00e9szv\u00e9nyt\u00e1rsas\u00e1g assignee.Racemization and enantiomer separation of clopidogrel. United States patent US 7 259 261.2007."},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja4096472"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/op700025d"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1344(200008)43:9<891::AID-JLCR373>3.0.CO;2-0"},{"key":"e_1_2_4_35_1","unstructured":"TarurVR SatheDG SawantKD.WO Patent 2006\/087729A1.2006."},{"key":"e_1_2_4_36_1","unstructured":"KimJS KimNH LeeNK LeeJY inventors; Sk Chemicals Co. Ltd. assignee.Process for the preparation of S\u2010(+)\u2010clopidogrel by optical resolution. United States patent US 7 696 351.2010."},{"key":"e_1_2_4_37_1","article-title":"Process for the preparation of (S)\u2010(+)\u2010clopidogrel by optical resolution","author":"Kim NH","year":"2007","journal-title":"PCT Int. Appl."},{"key":"e_1_2_4_38_1","unstructured":"YamamotoS FujiiA MitsudaM.U.S. Patent application2011:016."},{"key":"e_1_2_4_39_1","unstructured":"StohandlJ FrantisekJ NessW inventors; Ratiopharm Gmbh assignee.Stereoselective method for the production of Clopidogrel. United States patent US 7 507 827.2009."},{"key":"e_1_2_4_40_1","unstructured":"SoonookH SunhoH. PCT Application WO2007\/126258A1."},{"key":"e_1_2_4_41_1","unstructured":"BhushanLV BhushanLB BipinP.Preparation of clopidogrel. Indian 2004 IN 193668 A1 20040731."},{"key":"e_1_2_4_42_1","article-title":"Procedure for the preparation of methyl (+)\u2010(S)\u2010\u03b1\u2010(o\u2010chlorophenyl)\u20106,7\u2010dihydrothieno[3,2\u2010c]pyridine\u20105(4H)\u2010acetate","author":"Reddy BS","year":"2008","journal-title":"Eur. Pat. Appl."},{"key":"e_1_2_4_43_1","unstructured":"SajjaE AnumulaRR GillaG MadivadaLR inventors.Process for preparing clopidogrel. United States patent application US 11\/691 295.2007."},{"key":"e_1_2_4_44_1","unstructured":"ReddyAA RaoKV KumariAS et al.WO Patent 2007\/094006 A1.2007."},{"key":"e_1_2_4_45_1","first-page":"479","article-title":"An efficient and large scale synthesis of clopidogrel: Antiplatelet drug","volume":"4","author":"Madivada LR","year":"2012","journal-title":"Der Pharm Chem"},{"key":"e_1_2_4_46_1","unstructured":"HorneSE WeeratungaG ComanitaBM NagireddyJR McConachieLK inventors; Brantford Chemicals Inc. assignee.Process for the preparation of tetrahydrothieno [3 2\u2010c] pyridine derivatives. United States patent US 6 495 691.2002."},{"key":"e_1_2_4_47_1","doi-asserted-by":"crossref","unstructured":"SmyjPR WeeratungaG.U.S. Patent 7 060 831.2006.","DOI":"10.1088\/1126-6708\/2006\/11\/060"},{"key":"e_1_2_4_48_1","unstructured":"Banerjee K. Jain M. Ballabh A. et al.A novel process for the preparation of clopidogrel base and its benzenesulfonic acid salt2014;5:1371\u20131380."},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.4816"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614133"},{"key":"e_1_2_4_51_1","first-page":"313","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"72","author":"Savi P","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300038c"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/op900243c"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/op1001116"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja7106349"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200802468"},{"key":"e_1_2_4_57_1","unstructured":"HwangSO KimYJ inventors; Enzytech Ltd. assignee.Method for preparing clopidogrel and its derivatives. United States patent application US 12\/996 733.2009."},{"key":"e_1_2_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetasy.2010.06.040"},{"key":"e_1_2_4_59_1","unstructured":"KumarA VyasKD BarveSG et al.PCT Int. Appl WO 2005104663 A2.2005."},{"key":"e_1_2_4_60_1","unstructured":"RamasubbuC MamidalaR ArjunanD et al.An improved process for the preparation of clopidogrel. PCT Int. Appl.2007 WO 2007144729 A1 20071221."},{"key":"e_1_2_4_61_1","unstructured":"BurgerW GudaparthiO ReddyKS et al.Process for preparation of clopidogrel bisulfate crystalline form\u20101. PCT Int. Appl.2011 WO 2011055378 A1 20110512."},{"key":"e_1_2_4_62_1","unstructured":"ValerianoM DaverioP BianchiS inventors; Teva Pharmaceutical Industries Ltd. assignee.Racemization and enantiomer separation of clopidogrel. United States patent US 6 737 411.2004."},{"key":"e_1_2_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.05.059"},{"key":"e_1_2_4_64_1","unstructured":"LeeJY KimNH KimJ\u2010S LeeNK.Process for the preparation of (S)\u2010(+)\u2010clopidogrel on a solid\u2010phase. PCT Int. Appl.2007 WO 2007073095 A1 20070628."},{"key":"e_1_2_4_65_1","article-title":"Facile solid\u2010phase synthesis of (+)\u2010(S)\u2010clopidogrel","volume":"96","author":"Kiwon J","year":"2013","journal-title":"Helv Chim Acta"},{"key":"e_1_2_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jorganchem.2009.02.008"},{"key":"e_1_2_4_67_1","unstructured":"BousquetA MusolinoA inventors; Sanofi\u2010Synthelabo assignee.Hydroxyacetic ester derivatives preparation method and use as synthesis intermediates. United States patent US 6 573 381.2003."},{"key":"e_1_2_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchem.651"},{"key":"e_1_2_4_69_1","unstructured":"CastaldiG BarrecaG BolognaA inventors; Dipharma SpA assignee.Process for the preparation of clopidogrel. United States patent US 7 329 751.2008."},{"key":"e_1_2_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2012.06.097"},{"key":"e_1_2_4_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-009-2286-z"},{"key":"e_1_2_4_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/ol052212c"},{"key":"e_1_2_4_73_1","doi-asserted-by":"publisher","DOI":"10.1039\/b703463f"},{"key":"e_1_2_4_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/adsc.200800292"},{"key":"e_1_2_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-010-0396-4"},{"key":"e_1_2_4_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejoc.201100107"},{"key":"e_1_2_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2009.12.003"},{"key":"e_1_2_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biortech.2009.09.003"},{"key":"e_1_2_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-010-2941-4"},{"key":"e_1_2_4_80_1","first-page":"635,763","article-title":"Process to prepare clopidogrel","volume":"6","author":"Pandey B","year":"2003","journal-title":"US Patent"},{"key":"e_1_2_4_81_1","doi-asserted-by":"publisher","DOI":"10.1039\/C4CC07643E"},{"key":"e_1_2_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bej.2013.03.005"},{"key":"e_1_2_4_83_1","unstructured":"ArulR RawatAJ AjayS et al.Preparation of clopidogrel crystalline polymorphs for inhibiting platelet aggregation. PCT Int. Appl.2005 WO 2005026174 A1 20050324."},{"key":"e_1_2_4_84_1","unstructured":"ReddyMS KumarMK RajanS et al.An improved process for the preparation of clopidogrel and its pharmaceutically\u2010acceptable salts. PCT Int. Appl.2008 WO 2008004249 A2 20080110."},{"key":"e_1_2_4_85_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1316852"},{"key":"e_1_2_4_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo300642z"},{"key":"e_1_2_4_87_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1083239"},{"key":"e_1_2_4_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/00397911.2015.1061671"},{"key":"e_1_2_4_89_1","first-page":"1","article-title":"ZnO nanoparticle as catalyst for efficient green synthesis of antiplatelet drug (clopidogrel)","volume":"1","author":"Gharib A","year":"2014","journal-title":"J Chem Eng Chem Res"},{"key":"e_1_2_4_90_1","unstructured":"NadkarniSS PatelHM.Preparation of clopidogrel and its salts for pharmaceuticals. PCT Int. Appl.2004 WO 2004074215 A1 20040902."},{"key":"e_1_2_4_91_1","unstructured":"DholakiaPN DaveNG et al.Preparation of (S)\u2010(+)\u2010clopidogrel. PCT Int. Appl.2007 WO 2007144895 A1 20071221."},{"key":"e_1_2_4_92_1","unstructured":"PandyaB AryanRC RathodP KhanduriCH.Preparation of (S)\u2010clopidogrel. Indian Pat. Appl.2007 IN 2006DE01105 A 20071109."},{"key":"e_1_2_4_93_1","unstructured":"KimNH LeeJY KimJ\u2010S LeeNK.Process for preparation of (S)\u2010(+)\u2010clopidogrel. PCT Int. Appl.2008 WO 2008018779 A1 20080214."},{"key":"e_1_2_4_94_1","unstructured":"JiangW NiS ShiW FamingZS.A process for preparing intermediates of clopidogrel bisulfate via racemization of mother liquors from chiral resolution.2010CN 101812071 A 20100825."}],"container-title":["Chirality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fchir.22742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/chir.22742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:51:55Z","timestamp":1696035115000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/chir.22742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/chir.22742"],"URL":"https:\/\/doi.org\/10.1002\/chir.22742","archive":["Portico"],"relation":{},"ISSN":["0899-0042","1520-636X"],"issn-type":[{"value":"0899-0042","type":"print"},{"value":"1520-636X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,6]]}}}